Source
Investing.com
LOS ANGELES - Immix Biopharma, Inc. (NASDAQ:IMMX) announced today the completion of enrollment in its NEXICART-2 trial, a Phase 2 study evaluating CAR-T therapy NXC-201 for relapsed/refractory AL amyloidosis.
The company expects topline results from the 40-patient study in the third quarter of 2026, followed by a Biologics License Application (BLA) submission to the FDA, according to a press release statement.
AL amyloidosis is a disease in which the immune system produces toxic light chains that accumulate in organs including the heart, kidney and liver, potentially causing organ failure. The company estimates approximately 38,500 patients in the U.S. have relapsed/refractory AL amyloidosis in 2026.
News Url